
Maximilian Merz
Articles
-
Feb 21, 2025 |
nature.com | Maximilian Merz |David Fandrei |Eva Heger |Viola Schweinsberg |Uwe Platzbecker |Michael Hallek | +3 more
AbstractChimeric antigen receptor (CAR) T cells and bispecific T cell engagers have become integral components in the treatment of relapsed/refractory multiple myeloma. We report a 63-year-old male who received ciltacabtagene autoleucel CAR T cells and the GPRC5D × CD3 bispecific talquetamab for early relapse of his multiple myeloma. Nine months after CAR T therapy, he developed a symptomatic leukemic peripheral T cell lymphoma with cutaneous and intestinal involvement.
-
Dec 8, 2024 |
fnweb.de | Maximilian Merz
Die Merlins Crailsheim haben in der 2. Basketball-Bundesliga „Pro A“ gegen Rasta Vechta II nach zuletzt drei Heimniederlagen verdient mit 95:69 gewonnen. Der erste Durchgang gehörte dabei eindeutig den „Zauberern“, die sich angeführt von Vize-Kapitän Vinnie Shahid über 20 Minuten absetzten. Die Crailsheimer Überlegenheit des ersten Durchgangs setzte sich auch in den zweiten 20 Minuten weiter durch und endete in einem erlösenden Heimsieg.
-
Dec 4, 2024 |
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 4, 2024 |
nature.com | Sarah Flossdorf |Sandra Sauer |Hartmut Goldschmidt |Monika Engelhardt |Robert Zeiser |Vladan Vucinic | +5 more
AbstractIdentifying patients who may benefit from autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and consolidation strategies. We analyzed data from 12763 patients enrolled in the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), distinguishing those who underwent single (n = 8736) or tandem ASCT (n = 4027) from 1998 to 2021.
-
Dec 4, 2024 |
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →